Heme Oxygenase-l Induced by Aprotinin Inhibits Vascular Smooth Muscle Cell Proliferation Through Cell Cycle Arrest in Hypertensive Rats

  • Choi, Hyoung-Chul (Departments of Pharmacology, College of Medicine, Yeungnam University) ;
  • Lee, Kwang-Youn (Departments of Pharmacology, College of Medicine, Yeungnam University) ;
  • Lee, Dong-Hyup (Departments of Thoracic and Cardiovascular Surgery, College of Medicine, Yeungnam University) ;
  • Kang, Young-Jin (Departments of Pharmacology, College of Medicine, Yeungnam University)
  • Published : 2009.08.31

Abstract

Spontaneous hypertensive rats (SHR) are an established model of genetic hypertension. Vascular smooth muscle cells (VSMC) from SHR proliferate faster than those of control rats (Wistar-Kyoto rats; WKY). We tested the hypothesis that induction of heme oxygenase (HO)-1 induced by aprotinin inhibits VSMC proliferation through cell cycle arrest in hypertensive rats. Aprotinin treatment inhibited VSMC proliferation in SHR more than in normotensive rats. These inhibitory effects were associated with cell cycle arrest in the G1 phase. Tin protoporphyrin IX (SnPPIX) reversed the anti-proliferative effect of aprotinin in VSMC from SHR. The level of cyclin D was higher in VSMC of SHR than those of WKY. Aprotinin treatment downregulated the cell cycle regulator, cyclin D, but upregulated the cyclin-dependent kinase inhibitor, p21, in VSMC of SHR. Aprotinin induced HO-1 in VSMC of SHR, but not in those of control rats. Furthermore, aprotinin-induced HO-1 inhibited VSMC proliferation of SHR. Consistently, VSMC proliferation in SHR was significantly inhibited by transfection with the HO-1 gene. These results indicate that induction of HO-1 by aprotinin inhibits VSMC proliferation through cell cycle arrest in hypertensive rats.

Keywords

References

  1. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97: 364−372, 1989
  2. Chang T, Wu L, Wang R. Inhibition of vascular smooth muscle cell proliferation by chronic hemin treatment. Am J Physiol Heart Circ Physiol 295: H999−H1007, 2008 https://doi.org/10.1152/ajpheart.01289.2007
  3. Dong Y, Chi SL, Borowsky AD, Fan Y, Weiss RH. Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal 16: 263−269, 2004 https://doi.org/10.1016/S0898-6568(03)00136-0
  4. Duckers HJ, Boehm M, True al., Yet SF, San H, Park JL, Clinton Webb R, Lee ME, Nabel GJ, Nabel EG. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 7: 693−698, 2001 https://doi.org/10.1038/89068
  5. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257: 1958−1961, 1992 https://doi.org/10.1126/science.1329201
  6. Englberger L, Kipfer B, Berdat PA, Nydegger UE, Carrel TP. Aprotinin in coronary operation with cardiopulmonary bypass: does 'low-dose' aprotinin inhibit the inflammatory response? Ann Thorac Surg 73: 1897−1904, 2002 https://doi.org/10.1016/S0003-4975(02)03535-X
  7. Hunter T. Braking the cycle. Cell 75: 839−841, 1993 https://doi.org/10.1016/0092-8674(93)90528-X
  8. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 38: 581−587, 2001 https://doi.org/10.1161/hy09t1.096249
  9. Jeon EM, Choi HC, Lee KY, Chang KC, Kang YJ. Hemin inhibits hypertensive rat vascular smooth muscle cell proliferation through regulation of cyclin D and p21. Arch Pharm Res 32: 375−382, 2009 https://doi.org/10.1007/s12272-009-1310-2
  10. Lee DH, Choi HC, Lee KY, Kang YJ. Aprotinin inhibits vascular smooth muscle cell inflammation and proliferation via induction of HO-1. Korean J Physiol Pharmacol 13: 123−130, 2009 https://doi.org/10.4196/kjpp.2009.13.2.123
  11. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 72: S1814−1820, 2001 https://doi.org/10.1016/S0003-4975(01)03218-0
  12. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354: 353−365, 2006 https://doi.org/10.1056/NEJMoa051379
  13. McEvoy MD, Taylor AG, Zavadzkas JA, Mains IM, Ford RL, Stroud RE, Jeffords LB, Beck CU, Reeves ST, Spinale FG. Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion. Ann Thorac Surg 86: 568−575, 2008 https://doi.org/10.1016/j.athoracsur.2008.04.025
  14. Ndisang JF, Wu L, Zhao W, Wang R. Induction of heme oxygenase-1 and stimulation of cGMP production by hemin in aortic tissues from hypertensive rats. Blood 101: 3893−3900, 2003 https://doi.org/10.1182/blood-2002-08-2608
  15. Ndisang JF, Zhao W, Wang R. Selective regulation of blood pressure by heme oxygenase-1 in hypertension. Hypertension 40: 315−321, 2002 https://doi.org/10.1161/01.HYP.0000028488.71068.16
  16. Ngaage DL, Cale AR, Cowen ME, Griffin S, Guvendik L. Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study. Ann Thorac Surg 86: 1195−1202, 2008 https://doi.org/10.1016/j.athoracsur.2008.06.048
  17. Peyton KJ, Reyna SV, Chapman GB, Ensenat D, Liu XM, Wang H, Schafer AI, Durante W. Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth. Blood 99: 4443−4448, 2002 https://doi.org/10.1182/blood.V99.12.4443
  18. Resink TJ, Scott-Burden T, Baur U, Buhler FR. Increased proliferation fate and phosphoinositide turnover in cultured smooth muscle cells from spontaneously hypertensive rats. J Hypertens Suppl 5: S145−148, 1987 https://doi.org/10.1097/00004872-198712004-00025
  19. Sherr CJ. Cancer cell cycles. Science 274: 1672−1677, 1996 https://doi.org/10.1126/science.274.5293.1672
  20. Sherr CJ. Mammalian G1 cyclins. Cell 73: 1059−1065, 1993 https://doi.org/10.1016/0092-8674(93)90636-5
  21. Taille C, Almolki A, Benhamed M, Zedda C, Megret J, Berger P, Leseche G, Fadel E, Yamaguchi T, Marthan R, Aubier M, Boczkowski J. Heme oxygenase inhibits human airway smooth muscle proliferation via a bilirubin-dependent modulation of ERK1/2 phosphorylation. J Biol Chem 278: 27160−27168, 2003 https://doi.org/10.1074/jbc.M300364200
  22. Tanner FC, Greutert H, Barandier C, Frischknecht K, Luscher TF. Different cell cycle regulation of vascular smooth muscle in genetic hypertension. Hypertension 42: 184−188, 2003 https://doi.org/10.1161/01.HYP.0000082360.65547.7C
  23. Wang R, Shamloul R, Wang X, Meng Q, Wu L. Sustained normalization of high blood pressure in spontaneously hypertensive rats by implanted hemin pump. Hypertension 48: 685−692, 2006 https://doi.org/10.1161/01.HYP.0000239673.80332.2f
  24. Westaby S. Aprotinin in perspective. Ann Thorac Surg 55: 1033−1041, 1993 https://doi.org/10.1016/0003-4975(93)90149-C